Jiangzhong Pharmaceutical (600750.SH): It is proposed to acquire 51% of the equity of Haisi Pharmaceutical by equity transfer and capital increase

On September 17, 600750.SH Gelonghui announced that the company intends to acquire 51% of the equity of Jincheng Haisi Pharmaceutical Co., Ltd. ("Hais Pharmaceutical") by way of equity transfer and capital increase; of which it intends to acquire 36% of the equity of Hais Pharmaceutical through public delisting (25.7102% of Hais Pharmaceutical held by Jinneng Holding Equipment Manufacturing Group Co., Ltd. and 10.2898% of Hais Pharmaceutical held by Jincheng Wangtaike Industry and Trade Co., Ltd.); if the delisting is successful, The follow-up plan will increase the proportion of shares held by Hayes Pharmaceutical from 36% to 51% through capital increase; the total amount of the transaction price is expected to be 220.234338 million yuan, and the source of funds is the company's own funds. (The final transaction price is subject to the actual transaction price)

According to the announcement, Hayes Pharmaceutical is mainly engaged in the research and development of chemical drugs, mainly therapeutic chemical drugs, with the production conditions for the production of biological agents, oral solid preparations, small-volume injections, lyophilized powder injections, capsules, granules and other dosage forms and APIs. The company's core products are "Befida" bifidobacterium tripartite enteric-coated capsules, rabeprazole sodium enteric-coated tablets, bromoxine hydrochloride for injection, voriconazole for injection, etc. Among them, the OTC product "Befida" bifidobacterium tripartite enteric-coated capsules are the national basic drug list and the national medical insurance directory products, which are mainly used for the treatment of acute and chronic diarrhea and constipation caused by intestinal microbiota disorders. According to data from The Intranet, the sales of "Befida" bifidobacterium tripartite enteric-coated capsules in 2020 ranked 4th in domestic microecological preparations.

After the completion of this transaction, it is conducive to enriching the company's product structure with the help of Hays Pharmaceutical's products, improving the company's gastrointestinal business layout, enhancing the extensive coordination and resource integration of the two sides in terms of brands, products and terminals, and enhancing the company's profitability.

This article originated from Grand Gateway